Chronic urticaria in the real-life clinical practice setting in the UK: results from the noninterventional multicentre AWARE study
Open Access
- 1 December 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 45 (8), 1003-1010
- https://doi.org/10.1111/ced.14230
Abstract
Background Chronic urticaria (CU) is a skin condition characterized by repeated occurrence of itchy weals and/or angio-oedema for > 6 weeks. Aim To provide data demonstrating the real-life burden of CU in the UK. Methods This UK subset of the worldwide, prospective, noninterventional AWARE study included patients aged 18-75 years diagnosed with H1-antihistamine (H1-AH)-refractory chronic spontaneous urticaria (CSU) for > 2 months. Baseline characteristics, disease activity, treatments, comorbidities and healthcare resource use were documented. Quality of life (QoL), work productivity and activity impairment were assessed. Results Baseline analysis included 252 UK patients. Mean age and body mass index were 45.0 years and 29.0 kg/m(2), respectively. Most patients were female (77.8%) and had moderate/severe disease activity (mean Urticaria Activity Score over 7 days was 18.4) and a 'spontaneous' component to their CU (73.4% CSU; 24.6% CSU and chronic inducible urticaria). Common comorbidities included depression/anxiety (24.6%), asthma (23.8%) and allergic rhinitis (12.7%). A previous treatment was recorded for 57.9% of patients. Mean Dermatology Life Quality Index score was 9.5, and patients reported impairments in work productivity and activity. Healthcare resource use was high. Severity of CSU was associated with female sex, obesity, anxiety and diagnosis. Only 28.5% of patients completed all nine study visits, limiting analysis of long-term treatment patterns and disease impact. Conclusions Adult H1-AH-refractory patients with CU in the UK reported high rates of healthcare resource use and impairment in QoL, work productivity and activity at baseline. The differing structures of UK healthcare may explain the high study discontinuation rates versus other countries.Funding Information
- Novartis Pharmaceuticals UK Limited
This publication has 19 references indexed in Scilit:
- Patient-reported impact of chronic urticaria compared with psoriasis in theUnited StatesJournal of Dermatological Treatment, 2016
- Epidemiology of chronic spontaneous urticaria: results from a nationwide, population-based study in ItalyBritish Journal of Dermatology, 2016
- Economic Burden of Chronic Spontaneous Urticaria And Psoriasis: Patients Perspective From EuropeValue in Health, 2015
- Disease Activity Only Moderately Correlates with Quality of Life Impairment in Patients with Chronic Spontaneous UrticariaDermatology, 2013
- Diagnosis and Treatment of Urticaria and Angioedema: A Worldwide PerspectiveWorld Allergy Organization Journal, 2012
- Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report1Allergy, 2010
- How to assess disease activity in patients with chronic urticaria?Allergy, 2008
- The impact of chronic urticaria on the quality of lifeBritish Journal of Dermatology, 1997
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994
- The Validity and Reproducibility of a Work Productivity and Activity Impairment InstrumentPharmacoEconomics, 1993